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Abstract
Introduction The purpose of this study was to perform a
systematic review and meta-analysis of exogenous surfactant
administration to assess whether this therapy may be useful in
adult patients with acute respiratory distress syndrome.
Methods We performed a computerized literature search from
1966 to December 2005 to identify randomized clinical trials.
The primary outcome measure was mortality 28–30 days after
randomization. Secondary outcome measures included a
change in oxygenation (PaO2:FiO2  ratio), the number of
ventilation-free days, and the mean duration of ventilation. Meta-
analysis was performed using the inverse variance method.
Results Two hundred and fifty-one articles were identified. Five
studies met our inclusion criteria. Treatment with pulmonary
surfactant was not associated with reduced mortality compared
with the control group (odds ratio 0.97; 95% confidence interval
(CI) 0.73, 1.30). Subgroup analysis revealed no difference
between surfactant containing surface protein or not – the
pooled odds ratio for mortality was 0.87 (95% CI 0.48, 1.58) for
trials using surface protein and the odds ratio was 1.08 (95% CI
0.72, 1.64) for trials without surface protein. The mean
difference in change in the PaO2:FiO2 ratio was not significant
(P = 0.11). There was a trend for improved oxygenation in the
surfactant group (pooled mean change 13.18 mmHg, standard
error 8.23 mmHg; 95% CI -2.95, 29.32). The number of
ventilation-free days and the mean duration of ventilation could
not undergo pooled analysis due to a lack of sufficient data.
Conclusion Exogenous surfactant may improve oxygenation but
has not been shown to improve mortality. Currently, exogenous
surfactant cannot be considered an effective adjunctive therapy
in acute respiratory distress syndrome.
Introduction
Acute respiratory distress syndrome (ARDS) is a common
cause of respiratory failure in the intensive care unit. Patients
with ARDS exhibit an intense inflammatory reaction centered
in the lung parenchyma, resulting in alveolar flooding and col-
lapse, in reduced lung compliance, in increased work of
breathing, and in severe impairments in gas exchange [1-4].
Patients with ARDS have an inhospital mortality rate ranging
from 34% to 60% [5]. Treatment of patients with ARDS is
largely supportive, and includes mechanical ventilation with
low tidal volumes [6], positive end expiratory pressure to open
collapsed alveoli [7], supplemental oxygen, and supportive
care of other organ system failures. Given the high mortality
rate of patients with ARDS, other therapies are clearly needed.
Administration of exogenous pulmonary surfactant is an
adjunctive therapy that may help adult patients with ARDS.
Pulmonary surfactant is produced by type II alveolar cells and
is composed of two major fractions: phospholipids (90%) and
surfactant-specific proteins (10%). Surfactant decreases alve-
ARDS = acute respiratory distress syndrome; CI = confidence interval; FiO2 = fraction of inspired oxygen; OR = odds ratio; PaO2 = partial pressure 
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olar surface tension, thereby preventing alveolar collapse and
allowing efficient gas exchange at low transpulmonary pres-
sures. Furthermore, surfactant has important roles in host
immune defense, through both specific and nonspecific mech-
anisms [8].
Patients with ARDS show injury to the alveolar epithelial bar-
rier with consequent surfactant dysfunction. Indeed, surfactant
recovered from bronchoalveolar lavage fluid from ARDS
patients has alterations of the phospholipid and fatty acid pro-
file, has decreased levels of surfactant-specific proteins, and
has impaired surface-tension-lowering properties. Causes of
this impairment include the inhibition of surfactant function by
protein-rich edema fluid, by surfactant lipid peroxidation, and
by surfactant protein degradation [1,9]. Given these abnormal-
ities, administration of exogenous pulmonary surfactant has
been considered a possible treatment option in adult patients
with ARDS [8].
The purpose of this study was to perform a systematic review
and meta-analysis of exogenous surfactant administration to
assess whether this therapy, as currently administered, may be
useful in adult patients with ARDS.
Materials and methods
Study identification
We performed a computerized search to identify articles that
compared treatment with exogenous pulmonary surfactant
against the usual therapy for patients diagnosed with ARDS.
For our analysis, we only included studies that were rand-
omized controlled clinical trials, that compared the use of
exogenous pulmonary surfactant to an appropriate control
group (defined as patients receiving standard therapy with or
without a placebo), that evaluated mortality and/or pulmonary
physiological parameters, and that used objective documenta-
tion of ARDS using accepted criteria at the time of the individ-
ual study publication. Abstracts, case reports, editorials,
nonhuman studies, and nonEnglish studies were excluded.
We performed a computerized literature search of MEDLINE
(1966–December 2005), EMBASE (1980–December 2005),
Cochrane Database of Systematic Reviews (1996–December
2005), Cochrane controlled trials register (1996–December
2005), and the Database of Abstracts and Reviews of Effects
(1994–December 2005) to identify clinical studies and sys-
tematic reviews. We conducted the search for human studies
using the following combination of exploded medical subject
headings and text words: ('adult respiratory distress syn-
drome' or 'acute respiratory distress syndrome' or 'ARDS') and
('pulmonary surfactant' or 'lung surfactant') and ('adult'). The
reference lists of all articles selected were then hand-searched
for additional citations missed in the search.
Study selection
Two authors (WJD, NTA) independently reviewed the
abstracts of the references identified to determine suitability
for inclusion. Studies that could potentially be included were
obtained and reviewed in detail. Examiners were not blinded to
authors, to institutions, or to journal name.
Data extraction
Information about relevant outcome measures was extracted
for each study. Our primary outcome measure was mortality
28–30 days after randomization. Secondary outcome meas-
ures included a change in oxygenation (specifically the change
in the ratio between the partial pressure of oxygen and the
fraction of inspired oxygen (PaO2:FiO2 ratio)), the number of
ventilation-free days, and the mean duration of ventilation. Fur-
thermore, the following data were extracted: method of rand-
omization; inclusion and exclusion criteria; details of surfactant
administration, including type of surfactant, dose, duration,
and delivery method; nature of control treatment; mean age or
age range; gender ratio; ARDS scoring system; etiologies of
ARDS; and ventilation strategy.
Methodologic quality was assessed using the Jadad scoring
system, which consists of items describing randomization (0–
2 points), blinding (0–2 points), and dropouts and withdrawals
(0–1 points) in reporting of a randomized controlled trial [10].
A higher score indicates improved reporting. One author
(WJD) extracted the data, which were reviewed by the two
other authors (NTA, DD). If disagreement occurred, all three
authors met to establish consensus. If relevant data were miss-
ing or unclear from a particular trial, we attempted to contact
the primary author of that study.
Statistical analysis
Meta-analysis was performed using the inverse variance
method. Statistical heterogeneity was evaluated using the Q
statistic with P < 0.1. The primary outcome was summarized
as the odds ratio (OR) with the 95% confidence interval (CI).
A fixed-effect model was used unless there was significant
heterogeneity, in which case we applied a random effects
model. We examined the influence of the method of delivery
and the type of surfactant on all trials using predetermined
sensitivity analyses. All statistical analyses were performed
using Stata Version 8.0 (Statacorp LP, College Station, Texas,
USA).
Ethics
Ethics approval and patient consent were not applicable for
this meta-analysis.
Results
Search Results
We initially identified 251 articles. Of these, we excluded 238
because titles or abstracts were not relevant. Thirteen studies
were retrieved for detailed review [11-23]. Four studies wereAvailable online http://ccforum.com/content/10/2/R41
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Table 1
Characteristics of the trials not eligible for meta-analysis
Reference Number of 
patients
Exclusion criteria Delivery method Type of surfactant Other remarks
Reines and 
colleagues, 1992 
[27]
49 Abstract only Aerosolized Exosurf (synthetic, no 
surfactant protein)
Published as an abstract. Placebo-
controlled. Trend for improvement in 
the PaO2:FiO2 ratio and mortality
MacIntyre and 
colleagues, 1994 
[26]
10 Abstract only. No 
control group. No 
data on oxygenation 
or mortality
Aerosolized Exosurf (synthetic, no 
surfactant protein)
Published as an abstract. Only 4.5% of 
aerosolized radiolabeled surfactant 
reached the lungs
Spragg and 
colleagues, 1994 
[15]
6 Crossover trial Bronchoscopic Porcine surfactant Trend for improved oxygenation. 
Findings of reduced inhibition of 
surfactant function in bronchoalveolar 
lavage fluid after surfactant 
replacement
Walmrath and 
colleagues, 1996 
[13]
10 No control group Bronchoscopic Alveofact (natural 
bovine surfactant)
Trend for improvement in oxygenation 
(PaO2:FiO2 ratio)
Pallua and 
colleagues, 1998 
[12]
4 No control group Bronchoscopic Alveofact (natural 
bovine surfactant)
Improved oxygenation (PaO2:FiO2 
ratio)
Wiswell and 
colleagues, 1999 
[11]
12 No control group Bronchoscopic Surfaxin (synthetic 
surfactant)
Surfactant administration was safe. 
FiO2 and positive end-expiratory 
pressure decreased after treatment 
initiation
Walmrath and 
colleagues, 2000 
[25]
41 Abstract only Intratracheal Venticute (rSP-C-
based surfactant)
Published as an abstract. Randomized. 
Trend for improvement in PaO2:FiO2 
ratio, number of ventilator-free days 
and successful weaning at 28 days in 
patients receiving surfactant
Kesecioglu and 
colleagues, 2001 
[22]
36 Abstract only Intratracheal Porcine surfactant Published as an abstract. Randomized. 
Surfactant administration was safe. 
PaO2:FiO2 ratio and survival were 
improved in surfactant group
Spragg and 
colleagues, 2001 
[24]
40 Abstract only Intratracheal Venticute (rSP-C-
based surfactant)
Published as an abstract. Randomized. 
Surfactant treatment may reduce 
acute pulmonary inflammation
Walmrath and 
colleagues, 2002 
[14]
27 No control group Bronchoscopic Alveofact (natural 
bovine surfactant)
Surfactant administration was safe. 
Improved PaO2:FiO2 ratio
Spragg and 
colleagues, 2002 
[23]
448 Abstract only Intratracheal Venticute (rSP-C-
based surfactant)
Published as an abstract. Randomized. 
Improved PaO2:FiO2 ratio. No 
mortality benefit
Gregory and 
colleagues, 2003 
[21]
22 Abstract only. No 
control group
Bronchoscopic Surfaxin (synthetic 
surfactant)
Published as an abstract. Procedure 
found to be safe and tolerable
rSP-C, recombinant surfactant protein C.
added from a hand search of articles and clinical trials [24-27].
Twelve studies were not eligible for analysis (Table 1): seven
were in abstract form only [21-27], four had no control group
[11-13,27], and one was a crossover trial [15]. Five studies
met our inclusion criteria (Table 2) [16-20]. The study by
Spragg and colleagues [20] included results from both a
North American trial and a European–South African trial. For
the purposes of our analysis, therefore, the data from the two
trials in this manuscript were assessed independently, result-
ing in the final analysis of data from six randomized controlled
trials [16-20].
Study characteristics
The studies were published from November 1994 to August
2004 (Table 2). All were multicenter trials. The number of
patients in each trial ranged from 39 to 725. Different doses of
surfactant were used in three trials [16,18,19].
In an effort to analyze the most comparable data, the surfactant
group in the study by Weg and colleagues [16] with the clos-
est dosing to the surfactant group in the study by Anzueto and
colleagues [17] was chosen for analysis. This resulted in the
exclusion of 17 patients.Critical Care    Vol 10 No 2    Davidson et al.
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A similar issue was found in the four trials using surfactant con-
taining surface protein. Specifically, in the trial by Spragg and
colleagues [19] the surfactant group chosen for analysis was
the group who were given the same dose of surfactant as the
two other trials [20] using the same type of surfactant (recom-
binant surface protein C). This resulted in the exclusion of 12
patients. In the trial by Gregory and colleagues [18] the group
that received the higher dose of surfactant was used for anal-
ysis. As a result, 24 patients were excluded from the analysis.
A total of 1,270 patients were analyzed in these six trials: 381
patients were given surfactant containing no surfactant protein
(two trials) [16,17]; 239 patients were given surfactant con-
taining recombinant surfactant protein C (three trials) [19,20];
and 19 patients were given bovine surfactant containing both
surfactant proteins B and C (one trial) [18].
All studies included ARDS resulting from sepsis. Two studies
only included patients with sepsis-related ARDS, both pulmo-
nary and nonpulmonary [16,17]. The remaining studies
included patients with other direct lung injury (aspiration) and
indirect lung injury (trauma or surgery, transfusions, pancreati-
tis, burns, and toxic injury).
Primary outcome (mortality at 28 or 30 days)
Overall, treatment with exogenous pulmonary surfactant was
not associated with reduced mortality compared with the con-
trol group (Figure 1 and Table 3). That is, compared with the
control group, the OR for mortality after treatment with sur-
factant was 0.97 (95% CI 0.73, 1.30). Subgroup analysis
revealed no difference between the aerosolized and intratra-
cheal instillation methods: OR 0.99 (95% CI 0.74, 1.32) and
0.87 (95% CI 0.48, 1.58), respectively (Table 3).
Furthermore, the OR for mortality was similar regardless of
whether the surfactant contained surface protein or not. That
is, the pooled OR for mortality was 1.08 (95% CI 0.72, 1.64)
for the two trials using surfactant without surface protein
[16,17], and was 0.87 (95% CI 0.48, 1.58) for the four trials
using surfactant containing surface protein B and/or protein C
[18-20] (Table 3).
Secondary outcomes
Due to the constraints of the published data, the mean differ-
ence in change in the PaO2:FiO2 ratio between the surfactant
and control groups could only be assessed at the 24-hour
mark following treatment administration. Three studies had
sufficient information to allow pooling of the PaO2:FiO2 data
[19,20]. These three trials studied a total of 488 patients (251
patients in the surfactant arm and 237 patients in the control
arm). A fixed-effect model was used because the Q test for
heterogeneity was not significant (P = 0.11). There was a
trend for the surfactant group to have improved oxygenation
compared with the controls. This did not achieve statistical
significance, however (pooled mean change 13.18 mmHg,
standard error 8.23 mmHg; 95% CI -2.95, 29.32) (Figure 2).
The number of ventilation-free days and the mean duration of
ventilation could not undergo pooled analysis due to a lack of
sufficient data.
Discussion
Adult patients with ARDS exhibit a reduction in the amount
and function of surface-active material recovered by broncho-
alveolar lavage. In addition, the phospholipid, fatty acid, and
apoprotein profiles of pulmonary surfactant are altered [1]. It
would therefore seem sensible that exogenous pulmonary sur-
factant would be a useful therapy in the treatment of ARDS.
Our meta-analysis of six randomized controlled trials, however,
demonstrated little utility of the therapy [16-20]. There was no
overall improvement in mortality (OR 0.97; 95% CI 0.73,
1.30). Furthermore, subgroup analysis of preparations with
surfactant proteins in addition to phospholipids did not dem-
onstrate improved outcomes (OR 0.87; 95% CI 0.48, 1.58).
In three of the studies we were able to assess the impact of
surfactant on oxygenation (for instance the PaO2:FiO2 ratio 24
hours following surfactant administration). Although there was
a trend to improved oxygenation, this did not reach statistical
significance (mean change 13.18 mmHg, standard error 8.23
mmHg; 95% CI -2.95, 29.32).
Our search for all published randomized controlled trials was
thorough. Each study was assessed for quality and was cho-
sen only if they were similar with respect to study participants
and outcome measure. Mortality was chosen as the primary
outcome given its importance in clinical practice. Unlike the
most recent published meta-analysis [28], we attempted to
assess oxygenation (PaO2:FiO2 ratio), the number of ventila-
tion-free days, and the mean duration of ventilation. Unfortu-
Figure 1
Forest plot of mortality Forest plot of mortality. This Forest plot represents the odds ratio (OR) 
(95% confidence interval) for 28-day to 30-day mortality in patients 
treated with surfactant compared with controls. OR < 1 indicates that 
treatment with surfactant was associated with a reduction in mortality 
compared with the control group, while OR > 1 indicates an increase in 
mortality with surfactant therapy. Areas of boxes are proportional to the 
respective study weight within the corresponding pooled analysis (see 
also weight values on the right). Eur-SA, European–South African trial; 
NA, North American trial.A
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Table 2
Characteristics of the trials eligible for meta-analysis
Article (Jadad 
score)
Design Number of 
patients
Delivery 
method
Type of 
surfactant
Surfactant dosing (total) Treatment 
duration
Number of deaths Ventilation-free daysa Duration of ventilationb
Control Surfactant Control Surfactant Control Surfactant
Weg and 
colleagues, 
1994 [16] 
(score 5)
Multicenter: 
USA, 
Canada
51 (control = 17, 
group 1 = 17, 
group 2 = 17)
Aerosolized Exosurf 
(synthetic, 
no 
surfactant 
protein)
13.5 mg DPPC/ml (group 
1, 21.9 mg DPPC/kg/
day; Group 2, 43.5 mg 
DPPC/kg/day)
Maximum 120 
hours for all 
groups
8G r o u p  1  =  7 ,  
group 2 = 6
NA NA NA NA
Anzueto and 
colleagues, 
1996 [17] 
(score 5)
Multicenter: 
USA, 
Spain, 
France
725 (control = 
361, surfactant 
= 364)
Aerosolized Exosurf 
(synthetic, 
no 
surfactant 
protein)
13.5 mg DPPC/ml (112 
mg DPPC/kg/day)
Maximum 5 
days
143 145 NA NA 16.4 (0.9) 16.0 (1.0)
Gregory and 
colleagues, 
1997 [18] 
(score 2)
Multicenter: 
USA
59 (control = 16, 
group 1 = 8, 
group 2 = 16, 
group 3 = 19)
Intratracheal Survanta 
bovine lung 
extract 
(containing 
SP-B and 
SP-C)
Group 1, 50 mg/kg LBW 
(maximum 8 doses); 
group 2, 100 mg/kg 
LBW (maximum 4 
doses); group 3, 100 
mg/kg LBW (maximum 
8 doses)
Maximum 96 
hours for all 
groups
7G r o u p  1  =  4 ,  
group 2 = 3, 
group 3 = 3
NA NA 10 Group 1 = 15c, 
group 2 = 7c, 
group 3 = 10c
Spragg and 
colleagues, 
2003 [19] 
(score 2)
Multicenter: 
USA, 
Canada
40 (control= 13, 
group 1 = 15, 
group 2 = 12)
Intratracheal Venticute 
(rSP-C-
based 
surfactant)
Group 1, 1 mg/kg LBW 
(maximum 4 doses); 
group 2, 0.5 ml/kg 
LBW (maximum 4 
doses)
24 hours for 
all groups
5G r o u p  1  =  3 ,  
group 2 = 4
6 (0–15) Group 1= 5 
(0–18), 
group 2 = 4 
(0–12)
NA NA
Spragg and 
colleagues, 
2004 [20] 
(score 4)
Multicenter: 
Europe, 
South 
Africa
227 (control = 
109, surfactant 
= 118)
Intratracheal rSP-C-based 
surfactant
1 mg/kg LBW (maximum 
4 doses)
24 hours 43 46 0 (0–20) 0 (0–19) NA NA
Spragg and 
colleagues, 
2004 [20] 
(score 4)
Multicenter: 
USA, 
Canada
221 (control = 
115, surfactant 
= 106)
Intratracheal rSP-C-based 
surfactant
1 mg/kg LBW (maximum 
4 doses)
24 hours 29 34 6 (0–21) 3.5 (0–21) NA NA
DPPC, dipalmitoylphosphatidylcholine; LBW, lean body weight; rSP-C, recombinant surfactant protein C; NA, not available.
aValues presented as median (25th–75th percentile).
bValues presented as mean (± standard deviation).
cValues presented as median.Critical Care    Vol 10 No 2    Davidson et al.
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nately, there were limited data available for analysis of the
change in oxygenation and insufficient data for assessment of
ventilation characteristics. It is possible that we may have
missed some published and unpublished articles.
The quality of the studies varied in our meta-analysis. Using the
Jadad scoring system [10], four of the studies were of high
quality (Jadad score 4 or 5) [16,17,20] but two studies were
not (Jadad score 2) [18,19] (Table 4). Of the latter two stud-
ies, one was a phase I/II prospective, randomized trial while
the other was open-labeled. Notably these two studies had the
lowest OR for mortality, and their exclusion, which would favor
the null hypothesis, would not have changed our results signif-
icantly.
A limitation of our analysis is the many differences among the
various studies. First, different types of surfactant were used.
Two of the studies used synthetic surfactant (Exosurf) contain-
ing no surfactant protein [16,17]. These studies have been
criticized given the emerging data on the importance of sur-
factant proteins in the proper functioning of surfactant [29,30].
It has been shown that surfactant-associated protein concen-
trations are decreased in bronchoalveolar lavage samples
obtained from patients with ARDS compared with samples
from control subjects [3]. Four surfactant proteins have been
previously identified (SP-A, SP-B, SP-C, and SP-D). SP-B and
SP-C are hydrophobic proteins that enhance the lowering of
surface tension [8]. In the three studies using protein-based
surfactant, two were recombinant preparations incorporating
SP-C [19,20] while the other was a bovine extract with both
SP-B and SP-C [18]. SP-A and SP-D are hydrophilic proteins
whose role appears to center around host defense [8]. None
of the trials in our analysis, however, used surfactant contain-
ing SP-A or SP-D. It is possible that the presence of these pro-
teins could increase the effectiveness of therapy.
Second, the different delivery methods used may have
resulted in varying concentrations of surfactant reaching the
damaged alveoli and altering the effectiveness of therapy. It
has been shown that the relative rate of pulmonary deposition
of surfactant is 4–5% using the aerosolization route
[17,29,30]. In the article by Anzueto and colleagues [17] this
would correspond to delivery of less than 5 mg/kg/day phos-
Figure 2
Forest plot of the PaO2:FiO2 ratio Forest plot of the PaO2:FiO2 ratio. This Forest plot represents the mean 
difference in the change in the PaO2:FiO2 ratio (mmHg) of surfactant 
compared with controls. A positive value (i.e. right of 0) indicates that 
treatment with surfactant resulted in improved oxygenation at 24 hours 
compared with controls. Areas of boxes are proportional to the respec-
tive study weight within the corresponding pooled analysis (see also 
weight values on the right). Eur-SA, European–South African trial; NA, 
North American trial.
Table 3
Principal outcome measures in patients according to type of surfactant and method of delivery
Outcome Number of 
trials
Number of patients Heterogeneity P value Fixed-effects 
model [odds ratio 
(95% CI)]
Random-effects 
model [odds ratio 
(95% CI)]
Control Surfactanta Q statistic I2
Overall mortality 6 631 639 6.00 0.17 0.31 0.99 (0.79, 1.25) 0.97 (0.73, 1.30)
Method of delivery
Aerosolized [16,17] 2 378 381 0.48 0 0.49 0.99 (0.74, 1.32) -
Intratracheal [18-20] 4 253 258 5.52 0.46 0.14 1.00 (0.69, 1.46) 0.87 (0.48, 1.58)
Type of surfactant
Synthetic [16,17] (no surfactant 
protein)
2 378 381 2.21 0.55 0.14 1.09 (0.74, 1.60) 1.08 (0.72, 1.64)
Recombinant [19,20] (SP-C) 3 237 239 0.36 0 0.84 0.99 (0.74, 1.32) -
Recombinant + bovine [18-20] 
(SP-B and SP-C)
4 253 258 5.52 0.46 0.14 1.00 (0.69, 1.46) 0.87 (0.48, 1.58)
aIn the studies by Weg and colleagues [16], Gregory and colleagues [18], and Spragg and colleagues [19], those patients who received a 
comparable surfactant dose (the higher dose) were used for the pooled analysis.Available online http://ccforum.com/content/10/2/R41
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pholipid, while other investigations have suggested that
administration of 300 mg/kg/day may be required [30]. The
ability of intratracheal administration, the method used by most
of the studies in this meta-analysis, to effectively deliver of sur-
factant to the alveoli is unclear. Delivery of surfactant using the
bronchoscopic route has been shown to be efficacious and
safe, with initial studies showing improved oxygenation and a
trend toward improved mortality [11-15]. None of the trials
using this method, however, met the inclusion criteria for our
analysis. Nevertheless, bronchoscopic administration may be
a potential promising path of future investigation.
Third, there were a variety of other differences between the
studies including ventilation strategies and the time to sur-
factant administration. In this meta-analysis, three studies uti-
lized the low tidal volume approach [19,20] while one trial
used traditional tidal volumes [18]. Two trials did not specify
the ventilation strategy used [16,17]. Most studies required
administration of surfactant within 48 hours of the diagnosis of
ARDS. One study allowed administration up to 72 hours after
ARDS was diagnosed [20]. The timing of administration is an
important issue as the response to early therapy versus
delayed therapy may be significant [3].
Finally, the populations that were studied included patients
with a wide variety of predisposing causes for ARDS. Patients
with ARDS associated with indirect causes, for example sep-
sis, trauma, or pancreatitis, have a greater number of poten-
tially fatal comorbidities than do patients with ARDS from
direct causes such as aspiration or pneumonia [20]. Sur-
factant is unlikely to prevent nonpulmonary causes of death,
and thus may only be effective in the subset of ARDS patients
with direct lung injury. In a recent study of pediatric patients
with acute lung injury, treatment with surfactant significantly
improved oxygenation and survival in the subgroup of patients
with direct acute lung injury, while having little effect on
patients with indirect acute lung injury [31]. To date, studies
focusing on the adult population with direct acute lung injury
have not been reported.
Our results confirm and extend those of Adhikari and col-
leagues [28], who recently published a meta-analysis of a vari-
ety pharmacologic agents (for instance prostaglandin E, N-
acetylcysteine, high-dose steroids, pulmonary surfactant, pen-
toxifylline) used in the treatment of ARDS and acute lung
injury. Their review had significant differences compared with
ours, however. First, five of the nine studies included in their
Table 4
Jadad scoring items and allocation concealment of each study eligible for meta-analysis
Weg and colleagues, 
1994 [16]
Anzueto and 
colleagues, 1996 
[17]
Gregory and 
colleagues, 1997 
[18]
Spragg and 
colleagues, 2003 
[19]
Spragg and 
colleagues, 2004 
[20]
Jadad scoring items
Was the study 
randomized?
Yes Yes Yes Yes Yes
Was the 
randomization 
method described 
and appropriate?
Yes Yes No Yes No
Was the study 
described as 
double-blind?
Yes Yes No No Yes
Was the method of 
blinding described 
and appropriate
Yes Yes No No Yes
Was there a 
description of 
withdrawals and 
dropouts?
Yes Yes Yes No Yes
Inappropriate method 
of randomization?
No No No No No
Inappropriate method 
of blinding?
No No No No No
Allocation 
concealment
Central office 
provided 
randomization 
assignment to study 
sites
Independent central 
facility provided 
randomization 
assignment to study 
sites
Not clearly stated Centralized facility 
provided 
randomization 
assignment to study 
sites
Not clearly statedCritical Care    Vol 10 No 2    Davidson et al.
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review were abstracts, several of which did not include a pla-
cebo group. Second, they were only able to assess early mor-
tality and did not include the change in the PaO2:FiO2 ratio.
Finally, they did not perform subgroup analyses. Despite these
methodologic differences, their results were consistent with
ours in that exogenous pulmonary surfactant was found to
have no significant effect on mortality (relative risk 0.93; 95%
CI 0.77, 1.12).
Conclusion
We found in our meta-analysis that exogenous surfactant may
improve oxygenation but did not improve mortality. Given the
abnormalities of surfactant function found in patients with
ARDS, the lack of effectiveness of exogenous surfactant is
somewhat surprising. One potential explanation is that
patients with ARDS usually die of multi-organ system failure
from their underlying disease process (for example sepsis)
rather than from respiratory failure per se. As such, treatment
of the pulmonary abnormalities may not affect mortality sub-
stantially. Evaluation of surfactant treatment of patients with
direct lung injury may clarify this issue. Another potential expla-
nation is that the proper 'surfactant recipe' has not yet been
found. That is, there may be a dose, formulation, and delivery
strategy of surfactant that could be effective in patients in
ARDS, potentially when combined with other therapies such
as lung protective ventilation [6], high-frequency ventilation
[32], prone positioning [33], or extracorporeal membrane oxy-
genation [34]. Future studies may eventually discover such an
approach, but exogenous surfactant cannot currently be con-
sidered an effective adjunctive therapy in ARDS.
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